DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
AuthorsCueto, F. J.
Del Fresno, C.
Combes, A. J.
Sánchez-Paulete, A. R.
Bromley, Christian P
Gomez, M. J.
AffiliationCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
MetadataShow full item record
AbstractBackground: Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in antitumor immunity has not been clarified yet. Methods: B16 and MC38 tumor cell lines were inoculated subcutaneously into wild-type (WT) and DNGR-1-deficient mice. To overexpress Flt3L systemically, we performed gene therapy through the hydrodynamic injection of an Flt3L-encoding plasmid. To characterize the immune response, we performed flow cytometry and RNA-Seq of tumor-infiltrating cDC1s. Results: Here, we found that cross-presentation of tumor antigens in the steady state was DNGR-1-independent. However, on Flt3L systemic overexpression, tumor growth was delayed in DNGR-1-deficient mice compared with WT mice. Of note, this protection was recapitulated by anti-DNGR-1-blocking antibodies in mice following Flt3L gene therapy. This improved antitumor immunity was associated with Batf3-dependent enhanced accumulation of CD8+ T cells and cDC1s within tumors. Mechanistically, the deficiency in DNGR-1 boosted an Flt3L-induced specific inflammatory gene signature in cDC1s, including Ccl5 expression. Indeed, the increased infiltration of cDC1s within tumors and their protective effect rely on CCL5/CCR5 chemoattraction. Moreover, FLT3LG and CCL5 or CCR5 gene expression signatures correlate with an enhanced cDC1 signature and a favorable overall survival in patients with cancer. Notably, cyclophosphamide elevated serum Flt3L levels and, in combination with the absence of DNGR-1, synergized against tumor growth. Conclusion: DNGR-1 limits the accumulation of tumor-infiltrating cDC1s promoted by Flt3L. Thus, DNGR-1 blockade may improve antitumor immunity in tumor therapy settings associated to high Flt3L expression.
CitationCueto FJ, del Fresno C, Brandi P, Combes AJ, Hernández-García E, Sánchez-Paulete AR, et al. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J Immunother Cancer. 2021 May;9(5):e002054.
JournalJournal for Immunotherapy of Cancer
- Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
- Authors: Wang Z, Xu F, Hu J, Zhang H, Cui L, Lu W, He W, Wang X, Li M, Zhang H, Xiong W, Xie C, Liu Y, Zhou P, Liu J, Huang P, Qin XF, Xia X
- Issue date: 2021 May
- DNGR-1(+) dendritic cells are located in meningeal membrane and choroid plexus of the noninjured brain.
- Authors: Quintana E, Fernández A, Velasco P, de Andrés B, Liste I, Sancho D, Gaspar ML, Cano E
- Issue date: 2015 Dec
- In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
- Authors: Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F
- Issue date: 2021 May
- Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity.
- Authors: Giampazolias E, Schulz O, Lim KHJ, Rogers NC, Chakravarty P, Srinivasan N, Gordon O, Cardoso A, Buck MD, Poirier EZ, Canton J, Zelenay S, Sammicheli S, Moncaut N, Varsani-Brown S, Rosewell I, Reis e Sousa C
- Issue date: 2021 Jul 22
- A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
- Authors: Oba T, Hoki T, Yamauchi T, Keler T, Marsh HC, Cao X, Ito F
- Issue date: 2020 Oct 1